Novartis’s PSMA-targeted radioligand has improved overall survival and progression-free survival in top-line results from the Phase III VISION study in prostate cancer, cementing the company's pioneering role in the therapeutic area.
Novartis AG's 177Lu-PSMA-617 has met both overall survival (OS) and radiographic progression-free survival (PFS) primary endpoints in the Phase III VISION study in prostate cancer, but the company is holding back, for now, on the extent of the therapeutic benefit of the candidate radiotherapy.
The Basel, Switzerland-based big pharma released the top-line results of the VISION study on 23 March, and said it would...
Create an account to read this article
Already a subscriber?
The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.
Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.
Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.
